Federal Court Finds Edwards Lifesciences’ Patents for Endovascular Graft Not Infringed By Cook (Canada) Inc. And W. L. Gore & Associates, Inc.

IRVINE, CA--(Marketwire - September 23, 2009) - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced the Court of Appeals for the Federal Circuit affirmed a previous court decision in favor of Cook Inc. and W. L. Gore & Associates, finding the companies did not infringe Edwards’ patents for modular or multi-part endovascular grafts for treatment of abdominal aortic aneurysms (AAA).

While the company is disappointed in the court’s ruling, it does not impact any of Edwards’ businesses because the company discontinued its AAA product line in April 2006. Another co-defendant in this case settled with Edwards in January 2006 under terms including a payment of $37.5 million.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring, with more than five decades of experience in partnering with clinicians to develop life-saving innovations. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies, which are sold in approximately 100 countries. The company’s global brands include Carpentier-Edwards, Cosgrove-Edwards, Edwards SAPIEN, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, Cosgrove-Edwards, Edwards SAPIEN, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.